1. Home
  2. NUVL vs CADE Comparison

NUVL vs CADE Comparison

Compare NUVL & CADE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVL
  • CADE
  • Stock Information
  • Founded
  • NUVL 2017
  • CADE 1876
  • Country
  • NUVL United States
  • CADE United States
  • Employees
  • NUVL N/A
  • CADE N/A
  • Industry
  • NUVL Biotechnology: Pharmaceutical Preparations
  • CADE Major Banks
  • Sector
  • NUVL Health Care
  • CADE Finance
  • Exchange
  • NUVL Nasdaq
  • CADE Nasdaq
  • Market Cap
  • NUVL 5.8B
  • CADE 6.5B
  • IPO Year
  • NUVL 2021
  • CADE N/A
  • Fundamental
  • Price
  • NUVL $77.76
  • CADE $33.91
  • Analyst Decision
  • NUVL Strong Buy
  • CADE Buy
  • Analyst Count
  • NUVL 10
  • CADE 11
  • Target Price
  • NUVL $119.60
  • CADE $39.55
  • AVG Volume (30 Days)
  • NUVL 482.8K
  • CADE 2.2M
  • Earning Date
  • NUVL 08-11-2025
  • CADE 07-23-2025
  • Dividend Yield
  • NUVL N/A
  • CADE 3.24%
  • EPS Growth
  • NUVL N/A
  • CADE N/A
  • EPS
  • NUVL N/A
  • CADE 2.82
  • Revenue
  • NUVL N/A
  • CADE $1,744,915,000.00
  • Revenue This Year
  • NUVL N/A
  • CADE $13.84
  • Revenue Next Year
  • NUVL N/A
  • CADE $10.66
  • P/E Ratio
  • NUVL N/A
  • CADE $12.04
  • Revenue Growth
  • NUVL N/A
  • CADE 42.82
  • 52 Week Low
  • NUVL $55.54
  • CADE $25.22
  • 52 Week High
  • NUVL $113.51
  • CADE $40.20
  • Technical
  • Relative Strength Index (RSI)
  • NUVL 43.20
  • CADE 46.92
  • Support Level
  • NUVL $77.41
  • CADE $34.71
  • Resistance Level
  • NUVL $83.50
  • CADE $36.65
  • Average True Range (ATR)
  • NUVL 3.08
  • CADE 0.99
  • MACD
  • NUVL -0.75
  • CADE -0.26
  • Stochastic Oscillator
  • NUVL 14.84
  • CADE 19.41

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About CADE Cadence Bank

Cadence Bank is a bank based in the United States. The operating segments are Corporate Banking segment focuses on C&I, business banking, and commercial real estate lending to clients in the geographic footprint, Community Banking segment provides a broad range of banking services through the branch network to serve the needs of community businesses and individual consumers in the geographic footprint, Mortgage segment includes mortgage banking activities of originating mortgage loans, selling mortgage loans in the secondary market and servicing the mortgage loans, Banking Services segment offers individuals, businesses, governmental institutions, and non-profit entities a widerange of solutions to help protect, grow, and transfer wealth, General Corporate and Other segment.

Share on Social Networks: